Landos Biopharma, Inc. Common Stock
LABP
LABP was delisted on the 23rd of May, 2024.
47 hedge funds and large institutions have $219M invested in Landos Biopharma, Inc. Common Stock in 2021 Q1 according to their latest regulatory filings, with 47 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
59.38% more ownership
Funds ownership: 0% → 59.38% (+59%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PA
Perceptive Advisors
New York
|
+$194M |
| 2 |
RI
RTW Investments
New York
|
+$55.8M |
| 3 |
LGM
Logos Global Management
San Francisco,
California
|
+$9.58M |
| 4 |
O
OrbiMed
New York
|
+$8.89M |
| 5 |
DM
Deerfield Management
New York
|
+$5.87M |
Top Sellers
LABP Hedge Fund Activity: Q1 2021 in Review
47 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Landos Biopharma, Inc. Common Stock (LABP) for Q1 2021, worth a combined $219M.
Buyers outnumbered sellers: 47 funds opened new LABP positions and 0 closed out — a net gain of 47 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Perceptive Advisors, opening a new position worth an estimated $194M.
- 47 institutional investors held Landos Biopharma, Inc. Common Stock (LABP) as of Q1 2021, up from 0 in Q4 2020.
- Funds reported $219M of Landos Biopharma, Inc. Common Stock stock for Q1 2021.
- 47 funds opened new Landos Biopharma, Inc. Common Stock positions in Q1 2021 and 0 closed out, a net change of +47 holders.
- The largest Landos Biopharma, Inc. Common Stock buyer in Q1 2021 was Perceptive Advisors, an estimated $194M added.
Based on aggregated 13F filings for Q1 2021.